Druggable targets in cytokine release syndromes
Carlos Luri-Rey 1 , Iñaki Eguren-Santamaria 2 , Ignacio Matos 3 , Pedro Berraondo 4 , Ignacio Melero 5
Bispecific T-cell engagers and CAR T-cells share the problem of eliciting acute systemic inflammation episodes known as Cytokine Release Syndrome (CRS).
Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without jeopardizing the antitumor therapeutic outcome.
CITA DEL ARTÍCULO Clin Cancer Res. 2023 Sep 1. doi: 10.1158/1078-0432.CCR-23-1975